EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.028 HKD | 0.00% |
|
+3.70% | -17.65% |
| 2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
| 2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
| Sales 2022 | 73.92M 9.47M 12.95M | Sales 2023 | 72.58M 9.29M 12.71M | Capitalization | 160M 20.5M 28.05M |
|---|---|---|---|---|---|
| Net income 2022 | 131M 16.77M 22.95M | Net income 2023 | 129M 16.52M 22.6M | EV / Sales 2022 | 2.42 x |
| Net cash position 2022 | 29.22M 3.74M 5.12M | Net cash position 2023 | 1.68M 215K 295K | EV / Sales 2023 | 2.18 x |
| P/E ratio 2022 |
1.99
x | P/E ratio 2023 |
1.52
x | Employees | 169 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.85% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +3.70% | ||
| Current month | +3.70% | ||
| 1 month | -3.45% | ||
| 3 months | -6.67% | ||
| 6 months | -31.71% | ||
| Current year | -17.65% |
1 week
0.03
0.03
1 month
0.030.03
Current year
0.030.05
1 year
0.030.07
3 years
0.030.20
5 years
0.030.47
10 years
0.030.73
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Xie
CEO | Chief Executive Officer | 61 | - |
Hong Wu
DFI | Director of Finance/CFO | 52 | - |
Yong Cheng
BRD | Director/Board Member | 61 | 13-12-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Lou
BRD | Director/Board Member | 66 | 08-10-05 |
Sau Kuen Wong
BRD | Director/Board Member | 61 | 08-04-30 |
Yi Xie
CEO | Chief Executive Officer | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.028 | 0.00% | 50,000 |
| 24-05-02 | 0.028 | +3.70% | 840,000 |
| 24-04-30 | 0.027 | -3.57% | 110,000 |
| 24-04-29 | 0.028 | +3.70% | 270,000 |
| 24-04-26 | 0.027 | 0.00% | 480,000 |
Delayed Quote Hong Kong S.E., May 03, 2024 at 04:09 am
More quotes
Extrawell Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Manufacturing segment is engaged in the development, manufacture and sales of pharmaceutical products. Its self-produced products include Transfer Factor Oral Solution, Wisk, ZhouBang and others. The Trading segment is engaged in the promotion and distribution of imported pharmaceuticals. Its imported products include Millibar and Skin Cap. The Gene Development segment is engaged in the commercial development and research, development of gene-related technologies.
Sector
Pharmaceuticals
Calendar
2024-06-27
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.65% | 8.57M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- 858 Stock
